Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Affimed N.V. (Nasdaq: AFMD) announced it will release its third quarter 2021 results on November 10, 2021, followed by a conference call at 8:30 a.m. EST. The call will discuss financial results and recent corporate developments. Interested parties can join by dialing +1 (409) 220-9054 for U.S. callers or +44 (0) 8000 323836 for international participants. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to target and kill tumors using patients' innate immune cells. The call will be accessible via webcast and will be archived for 30 days.
Positive
- Scheduled Q3 2021 earnings release implies ongoing operational transparency.
- Conference call to discuss financial results shows commitment to investor engagement.
Negative
- None.
Details
News Market Reaction – AFMD
The recorded move for AFMD in the trading session of this news was +2.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 2021, and host a conference call at 8:30 a.m. EST to discuss financial results and recent corporate developments.
The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6166004 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on Affimed’s website for 30 days after the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.